Novel Orally Administered Small Molecule (Xiflam) Targeting Auto- Inflammation in Patients with Intermediate AMD
Time: 9:30 am
day: Conference Day Two
Details:
- Understanding the pathological Cx43 hemichannel and its role in inflammasome mediated disease progression in intermediate AMD
- Clinically developing a novel oral therapy to inhibit the pathologically open Cx43 hemichannel to modulate ATP activation and perpetuation of the inflammasome.
- Sharing preclinical data showing the effect of Xiflam vs Placebo in maintaining retinal integrity and visual function, in a model of the Dry form of Macular Degeneration
